Direkt zum Inhalt
Merck

HNDG3MAG-36K

Millipore

MILLIPLEX® Human Neurodegenerative Disease Magnetic Bead Panel 3 - Neuroscience Multiplex Assay

The analytes available for this multiplex kit are: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1.

Synonym(e):

Human NeuroscienceProtein MultiplexAssay, Luminex® Human Neuroscience Panel, Millipore Human Neuroscience Immunoassay

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Qualitätsniveau

Speziesreaktivität

human

Hersteller/Markenname

Milliplex®

assay range

accuracy: 108%
(RANTES)

accuracy: 108%
(sICAM-1)

accuracy: 111%
(Cathepsin D)

accuracy: 123%
(PDGF-AA)

accuracy: 137%
(PDGF-AB/BB)

standard curve range: 2-10,000 pg/mL
(RANTES)

standard curve range: 2.4-10,000 pg/mL
(BDNF)

standard curve range: 2.4-10,000 pg/mL
(PAI-1 (total))

standard curve range: 2.4-10,000 pg/mL
(PDGF-AA)

standard curve range: 24-100,000 pg/mL
(Cathepsin D)

standard curve range: 24-100,000 pg/mL
(MPO)

standard curve range: 24-100,000 pg/mL
(NCAM)

standard curve range: 24-100,000 pg/mL
(PDGF-AB/BB)

standard curve range: 24-100,000 pg/mL
(sICAM-1)

standard curve range: 61-250,000 pg/mL
(sVCAM-1)

Methode(n)

multiplexing: suitable

Nachweisverfahren

fluorometric (Luminex xMAP)

Versandbedingung

wet ice

Allgemeine Beschreibung

The MILLIPLEX® Human Neurodegenerative Bead Panel 3 (HNDG3MAG-36K) is to be used for the simultaneous quantification of the following 10 analytes in any combination: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, and sVCAM-1. This kit may be used for the analysis of all above analytes in human serum, plasma, and cerebrospinal fluid samples.

Panel Type: Neuroscience

Spezifität

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Anwendung

  • Analytes: BDNF, Cathepsin D, MPO, NCAM, PAI-1 (total), PDGF-AA, PDGF-AB/BB, RANTES, sICAM-1, sVCAM-1
  • Recommended Sample type: Serum, plasma, or CSF
  • Recommended Sample dilution: 1:100 diluted serum/plasma or neat CSF
  • Assay Run Time: Overnight
  • Research Category: Neuroscience
  • Research Subcategory: Category Alzheimer′s Disease Nervous System Neurodegenerative Diseases

Leistungsmerkmale und Vorteile

Design your multiplex kit by choosing available analytes within this panel.

Verpackung

Everything you need in a single kit.

Lagerung und Haltbarkeit

Recommended storage for kit components is 2 - 8°C.

Sonstige Hinweise

Sensitivity: See kit protocol for individual sensitvities

Rechtliche Hinweise

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT RE 2

Zielorgane

Respiratory Tract

Lagerklassenschlüssel

10 - Combustible liquids


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Maren S Fragala et al.
Journal of strength and conditioning research, 28(8), 2079-2087 (2014-05-17)
Aerobic exercise has been shown to counteract age-related neurological decrements that are associated with cognitive and physical impairments. However, the effects of resistance exercise on cognition, reaction, and neurotrophins are largely unknown. We examined changes in spatial awareness, visual and
Carolina Segura et al.
Frontiers in neurology, 11, 656-656 (2020-08-15)
Rationale: The optimal modality, intensity, duration, frequency, and dose-response of exercise as a therapy for Parkinson's Disease (PD) are insufficiently understood. Objective: To assess the impact of a high-intensity tandem bicycle program on clinical severity, biomarkers, and functional MRI (fMRI)
Kiyokazu Atake et al.
Frontiers in psychiatry, 9, 232-232 (2018-06-14)
Background: Cognitive impairment in schizophrenia can result in considerable difficulty in performing functions of daily life or social rehabilitation. Cognitive impairment in schizophrenia is related to various factors, such as the psychotic severity, aging, medication, and brain-derived neurotrophic factor (BDNF).
Rita Capirossi et al.
International journal of molecular sciences, 21(23) (2020-12-03)
Although, biomarkers are regarded as an important tool for monitoring injury severity and treatment efficacy, and for predicting clinical evolution in many neurological diseases and disorders including spinal cord injury, there is still a lack of reliable biomarkers for the
Meike Dirks et al.
Transplant immunology, 58, 101248-101248 (2019-11-02)
While acute neurotoxic side effects of calcineurin inhibitors (CNI) are well-known, data upon long-term effects on brain structure and function are sparse. We hypothesize that long-term CNI therapy affects the neuroimmune system, thereby, increasing the risk of neurodegeneration. Here, we

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.